Wegovy Results: What the Clinical Studies Actually Show

Wegovy's approval came after one of the most comprehensive obesity drug trial programs ever conducted. Published clinical studies enrolled over 4,500 participants across multiple studies, generating robust data on weight loss, health improvements, and long-term outcomes. Here's what the research actually found.

The Landmark Weight Loss Study

The primary study enrolled 1,961 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. None had diabetes. Participants received either Wegovy 2.4mg weekly or placebo, combined with lifestyle intervention (reduced calorie diet and increased physical activity).

Key findings after 68 weeks:

• Clinically significant average weight loss with Wegovy, substantially greater than placebo
• One-third of participants achieved major weight reduction
• The vast majority of Wegovy participants lost at least 5% of body weight

These results were unprecedented for a medication-based weight loss intervention. Previous weight loss medications typically achieved much less. Source: Wilding JPH, et al. N Engl J Med. 2021.

Results in Type 2 Diabetes

A separate study examined 1,210 adults who had both obesity and type 2 diabetes—a population that historically struggles to lose weight with diet and exercise alone.

Key findings after 68 weeks:

• Meaningful weight loss with Wegovy, significantly greater than placebo
• HbA1c (blood sugar marker) improved substantially
• The majority of participants lost at least 5% of body weight
• Significant improvements in blood pressure and cholesterol

The lower weight loss compared to non-diabetic participants reflects the metabolic challenges of type 2 diabetes. Still, the weight loss in this population represents a major therapeutic advance.

Intensive Behavioral Therapy Combination

A dedicated study tested whether adding intensive behavioral therapy—including a low-calorie diet (1,000-1,200 calories initially), increased physical activity, and regular counseling—would boost results beyond Wegovy alone.

Key findings after 68 weeks:

• Average weight loss: 16.0% with combined approach vs. 5.7% with placebo + intensive therapy
• 75% lost at least 10% of body weight
• Nearly half (49%) lost at least 15% of body weight

This trial demonstrated that while Wegovy produces excellent results with standard lifestyle advice, motivated patients who commit to more intensive dietary and exercise changes can achieve even greater weight loss.

What Happens When You Stop?

A continuation study addressed a critical question: what happens when treatment ends? All 902 participants took Wegovy for 20 weeks to reach the maintenance dose. Then half continued Wegovy while half switched to placebo for 48 more weeks.

Key findings:

• Continuing Wegovy: Additional 7.9% weight loss (total ~17% from start)
• Switching to placebo: Regained 6.9% of lost weight
• Cardiometabolic improvements reversed with placebo

This trial confirmed what obesity specialists have long known: obesity is a chronic condition. The medication works as long as you take it. Stopping treatment typically leads to weight regain—not because of medication failure, but because the underlying biology of obesity persists.

Two-Year Data

A long-term study followed 304 participants for a full two years to assess long-term durability of weight loss.

Key findings at 104 weeks:

• Average weight loss: 15.2% maintained through year two
• 77% maintained at least 5% weight loss
• Continued improvements in blood pressure, waist circumference, and lipids

The two-year data shows that weight loss achieved with Wegovy is sustainable with continued treatment, contradicting concerns that effectiveness might wane over time.

Beyond Weight: Health Improvements

The published clinical studies measured more than just pounds lost. Across studies, Wegovy treatment produced:

Cardiovascular markers:

• Systolic blood pressure: Reduced by 5-7 mmHg on average
• Total cholesterol: Decreased by 5-7%
• Triglycerides: Reduced by 15-20%
• C-reactive protein (inflammation marker): Decreased by 50-60%

Metabolic improvements:

• Waist circumference: Reduced by 13-14 cm on average
• Fasting glucose: Improved significantly even in non-diabetics
• Insulin sensitivity: Enhanced across all studies

Quality of life:

• Physical function scores improved substantially
• Participants reported better mobility and reduced joint pain
• Surveys showed improved body image and self-esteem

SELECT: Cardiovascular Outcomes

The SELECT trial, published in 2023, examined whether semaglutide could prevent heart attacks and strokes in people with obesity and established cardiovascular disease—but without diabetes.

Key findings from over 17,000 participants:

• 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death)
• Benefits appeared independent of weight loss alone
• Risk reduction emerged early and continued throughout the trial

SELECT established that semaglutide doesn't just make people lighter—it makes them healthier in ways that translate to fewer heart attacks and strokes.

Who Responds Best?

Analysis of published clinical data reveals factors associated with greater weight loss:

• Higher baseline BMI correlated with greater absolute weight loss
• Women tended to lose slightly more than men
• Younger participants showed somewhat better responses
• Those without diabetes lost more than those with diabetes
• Better adherence to lifestyle modifications enhanced results

However, significant weight loss occurred across all subgroups. Individual variation exists, but most participants achieved clinically meaningful results.

Timeline of Results

Understanding when to expect results helps set realistic expectations:

• Weeks 1-4: Appetite reduction begins; 1-2kg loss typical
• Months 2-4: Weight loss accelerates during dose escalation; 3-5% loss expected
• Months 5-8: Steady weight loss at maintenance dose; approaching 10% loss
• Months 9-12: Weight loss continues; 12-15% loss typical
• Year 2: Weight stabilizes or continues slow decline; maintenance phase

Maximum weight loss typically occurs between months 12-18. After that, weight tends to stabilize at a new, lower set point as long as treatment continues.

The Evidence-Based Conclusion

The published clinical studies represent some of the strongest evidence ever generated for an obesity medication. Key takeaways:

• Average weight loss of 15% exceeds any previous medication
• One-third of patients lose 20% or more of their body weight
• Health benefits extend beyond weight to cardiovascular and metabolic markers
• Results are sustainable with continued treatment
• Stopping treatment leads to weight regain in most cases

For Nigerians struggling with obesity, these clinical results offer hope grounded in rigorous science. Wegovy works—the data leaves no doubt.